國立高雄大學圖資館 |

登入

回首頁 到查詢結果 [ subject:"Drug development." ]

Drug development in psychiatry

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Drug development in psychiatryedited by Matthew Macaluso, Sheldon H. Preskorn, Richard C. Shelton.
其他作者:	Macaluso, Matthew.
出版者:	Cham :Springer International Publishing :2023.
面頁冊數:	viii, 459 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Psychotropic drugsDevelopment.
電子資源:	https://doi.org/10.1007/978-3-031-21054-9
ISBN:	9783031210549$q(electronic bk.)

Drug development in psychiatry
Drug development in psychiatry[electronic resource] /edited by Matthew Macaluso, Sheldon H. Preskorn, Richard C. Shelton. - Cham :Springer International Publishing :2023. - viii, 459 p. :ill., digital ;24 cm. - Advances in neurobiology,v. 302190-5223 ;. - Advances in neurobiology ;v.4..

Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development -- The History of Drug Development in Psychiatry: A Lesson in Serendipity -- The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders -- Discovery and Development of Monoamine Transporter Ligands -- Drug Development for New Psychiatric Drug Therapies -- Post-Approval Research in Drug Development: Priorities and Practices -- Discovery of new transmitter systems and hence new drug targets -- Reverse engineering drugs -- Back to the Future of Neuropsychopharmacology -- Targeted Treatments for Fragile X Syndrome -- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders Diseases -- Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics -- The role of fMRI in drug development: an update -- Monoamine Oxidase B (MAO-B): A Target for Rational Drug Development in Schizophrenia Using PET Imaging as an Example -- Genomics in Treatment Development -- Increased Inflammation and Treatment of Depression: from Resistance to Reuse, Repurposing and Redesign -- Experimental medicine approaches in early phase CNS drug development.

This new book reviews clinical trial methodology as it pertains to drug development in psychiatry. The authors will describe the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The history of drug development in psychiatry is explored dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. The book will delineate how drug development in psychiatry has changed and adapted with the discovery of drugs with novel mechanisms of action. Drug Development in Psychiatry elucidates how biomarkers, genetics, and advances in neuroscience and neuroimaging have influenced drug development approaches, which will ultimately change the practice of psychiatry. The book charts the early years of drug discovery by chance observation, reviews the developments of the past 50 years of refined targeting of CNS drugs without the discovery of mechanistically new drugs, and looks to the discovery of mechanistically new drugs, the examination of new targets, genetics, and biomarkers.

ISBN: 9783031210549$q(electronic bk.)

Standard No.: 10.1007/978-3-031-21054-9doiSubjects--Topical Terms:

949439
Psychotropic drugs
--Development.

LC Class. No.: RM315 / .D78 2023

Dewey Class. No.: 615.788

Drug development in psychiatry
LDR:03419nmm a2200337 a 4500 001 642205
003 DE-He213
005 20230316133418.0
006 m d
007 cr nn 008maaau
008 231123s2023 sz s 0 eng d
020 $a 9783031210549$q(electronic bk.)
020 $a 9783031210532$q(paper)
024 7 $a 10.1007/978-3-031-21054-9 $2 doi
035 $a 978-3-031-21054-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RM315 $b .D78 2023
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 615.788 $2 23
090 $a RM315 $b .D794 2023
245 0 0 $a Drug development in psychiatry $h [electronic resource] / $c edited by Matthew Macaluso, Sheldon H. Preskorn, Richard C. Shelton.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a viii, 459 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in neurobiology, $x 2190-5223 ; $v v. 30
505 0 $a Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development -- The History of Drug Development in Psychiatry: A Lesson in Serendipity -- The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders -- Discovery and Development of Monoamine Transporter Ligands -- Drug Development for New Psychiatric Drug Therapies -- Post-Approval Research in Drug Development: Priorities and Practices -- Discovery of new transmitter systems and hence new drug targets -- Reverse engineering drugs -- Back to the Future of Neuropsychopharmacology -- Targeted Treatments for Fragile X Syndrome -- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders Diseases -- Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics -- The role of fMRI in drug development: an update -- Monoamine Oxidase B (MAO-B): A Target for Rational Drug Development in Schizophrenia Using PET Imaging as an Example -- Genomics in Treatment Development -- Increased Inflammation and Treatment of Depression: from Resistance to Reuse, Repurposing and Redesign -- Experimental medicine approaches in early phase CNS drug development.
520 $a This new book reviews clinical trial methodology as it pertains to drug development in psychiatry. The authors will describe the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The history of drug development in psychiatry is explored dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. The book will delineate how drug development in psychiatry has changed and adapted with the discovery of drugs with novel mechanisms of action. Drug Development in Psychiatry elucidates how biomarkers, genetics, and advances in neuroscience and neuroimaging have influenced drug development approaches, which will ultimately change the practice of psychiatry. The book charts the early years of drug discovery by chance observation, reviews the developments of the past 50 years of refined targeting of CNS drugs without the discovery of mechanistically new drugs, and looks to the discovery of mechanistically new drugs, the examination of new targets, genetics, and biomarkers.
650 0 $a Psychotropic drugs $x Development. $3 949439
650 0 $a Drug development. $3 190608
650 1 4 $a Neurochemistry. $3 197640
650 2 4 $a Pharmacology. $3 218135
650 2 4 $a Psychiatry. $3 201470
700 1 $a Macaluso, Matthew. $3 841298
700 1 $a Preskorn, Sheldon H. $3 841299
700 1 $a Shelton, Richard C. $3 949438
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Advances in neurobiology ; $v v.4. $3 560821
856 4 0 $u https://doi.org/10.1007/978-3-031-21054-9
950 $a Biomedical and Life Sciences (SpringerNature-11642)